Ibrance vs Cosentyx
Side-by-side drug price comparison from Medicare Part D data
Verdict
Cosentyx costs 67% less per claim than Ibrance ($3616.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Cosentyx at $3.1B.
| Metric | Ibrance | Cosentyx |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,816 | $3,616* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.5B | $3.1B |
| Total Claims | 418,000 | 864,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -5.6%* | 8.9% |
| Generic Available | Yes | Yes |
| Condition | Cancer | Autoimmune Diseases |
| Total Beneficiaries | 36,000 | 120,000 |
Cosentyx costs 67% less per claim than Ibrance ($3616.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Cosentyx at $3.1B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Ibrance and Cosentyx. What follows is the interpretation — which specific axes carry the most weight for Ibrance versus Cosentyx, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.